PMID- 18781705
OWN - NLM
STAT- MEDLINE
DCOM- 20081211
LR  - 20131121
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Linking)
VI  - 17
IP  - 11
DP  - 2008 Nov
TI  - Evaluation of body mass index, pre-vaccination serum progesterone levels and 
      anti-anthrax protective antigen immunoglobulin G on injection site adverse events 
      following anthrax vaccination in women.
PG  - 1060-7
LID - 10.1002/pds.1657 [doi]
AB  - BACKGROUND: In 2002, CDC initiated the Anthrax Vaccination Program (AVP) to 
      provide voluntary pre-exposure anthrax vaccination for individuals at high risk 
      for exposure to Bacillus anthracis spores. The AVP offered an opportunity to 
      investigate hypothesized reasons for a reported gender difference in injection 
      site adverse events (AEs) following anthrax vaccine adsorbed (AVA). OBJECTIVES: 
      To evaluate in women the impact of body mass index (BMI), pre-vaccination serum 
      progesterone levels, and pre-vaccination anti-anthrax protective antigen 
      immunoglobulin G concentrations (anti-PA IgG) on the occurrence of AEs following 
      subcutaneous AVA vaccination. METHODS: Participants' BMI was determined at 
      enrollment. Also, pre-vaccination blood samples were assayed for serum 
      progesterone and anti-PA IgG. Post-vaccination solicited AEs were recorded by 
      participants using a 4-day diary card. RESULTS: Obese group had an elevated risk 
      for arm soreness. Decreased pre-vaccination serum progesterone level was 
      associated with arm swelling. Increased pre-vaccination anti-PA IgG was 
      associated with itching on the arm; and within the obese group, was associated 
      with arm swelling, lump or knot, redness, soreness, and warmth. CONCLUSIONS: In 
      AVA vaccinated women, obesity was associated with arm soreness and decreased 
      pre-vaccination serum progesterone levels were associated with increased rate of 
      arm swelling. Increased pre-vaccination anti-PA IgG may be associated with an 
      increased frequency of itching on the arm, and in obese women, may increase the 
      occurrence of arm swelling, lump or knot, redness, and warmth. Administering AVA 
      according to a woman's menstrual phase may reduce the occurrence of certain 
      injection site reactions.
CI  - Copyright (c) 2008 John Wiley & Sons, Ltd.
FAU - Zhang, Yujia
AU  - Zhang Y
AD  - Division of Reproductive Health, National Center for Chronic Disease Prevention 
      and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, 
      USA.
FAU - Martin, Stacey W
AU  - Martin SW
FAU - Rose, Charles E Jr
AU  - Rose CE Jr
FAU - Biagini, Raymond E
AU  - Biagini RE
FAU - Franzke, Laura H
AU  - Franzke LH
FAU - Smith, Jerry P
AU  - Smith JP
FAU - Sammons, Deborah L
AU  - Sammons DL
FAU - Robertson, Shirley A
AU  - Robertson SA
FAU - McNeil, Michael M
AU  - McNeil MM
LA  - eng
GR  - Y1-ES-0001/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Anthrax Vaccines)
RN  - 0 (Antibodies, Bacterial)
RN  - 0 (Immunoglobulin G)
RN  - 4G7DS2Q64Y (Progesterone)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anthrax/*immunology
MH  - Anthrax Vaccines/administration & dosage/*adverse effects
MH  - Antibodies, Bacterial/*blood
MH  - Arm
MH  - *Body Mass Index
MH  - Edema/*etiology/immunology/metabolism
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/*blood
MH  - Injections
MH  - Male
MH  - Middle Aged
MH  - Obesity/blood/*complications/immunology
MH  - Odds Ratio
MH  - Progesterone/*blood
MH  - Pruritus/*etiology/immunology/metabolism
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sex Factors
MH  - Young Adult
EDAT- 2008/09/11 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/09/11 09:00
PHST- 2008/09/11 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/09/11 09:00 [entrez]
AID - 10.1002/pds.1657 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2008 Nov;17(11):1060-7. doi: 10.1002/pds.1657.